In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Research Peptide Spotlight: Calgri (Cagrilintide) is here! The long acting amylin analog that's blowing up in metabolic research. This powerhouse mimics your body's natural satiety hormone, helping dial down appetite and support Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Trial Scorecard: REDEFINE 1 and 2 Buy Cagrilintide 5mg 10mg Third Party Tested BioEdge Peptides